secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-104199
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Pharmaceuticals raises $707.7M in public offering of common shares and pre-funded warrants
--------------------------------------------------------------------------------

- Offered 12.2M common shares at $57.00 plus pre-funded warrants for 877,194 shares at $56.9999 each.
- Underwriters exercised option to purchase an additional 1.7M common shares in full.
- Net proceeds of approximately $707.7 million after underwriting discounts and estimated expenses.
- Offering closed on March 12, 2026; warrants have $0.0001 exercise price and are immediately exercisable.
- Lead underwriters include J.P. Morgan, Jefferies, TD Securities, Stifel, RBC Capital Markets, and William Blair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526104199/0001193125-26-104199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526104199/d97906d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-104199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer